Conditions: Rheumatoid Arthritis
Keywords: Rheumatoid Arthritis, RA, ACR, inflammatory joints
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 237
Healthy volunteers: no

Brief summary:
This study will assess at Week 16 the efficacy and safety of AIN457 at different doses in patients with active RA despite stable MTX therapy. Treatment will continue up to Week 48 with a safety follow-up at Week 60 to assess the long term efficacy and safety of AIN457 treatment in combination with MTX in RA.

Detailed description:

Arms:
arm 1: Secukinumab 25mg s.c. q4wk arm 2: Secukinumab 75mg s.c. q4wk arm 3: Secukinumab 150mg s. c. q4wk arm 4: Secukinumab 300mg s.c. q4wk arm 5: Secukinumab Placebo s.c. q4wk

Interventions: intervention 1: Secukinmab intervention 2: Placebo
Intervention descriptions: intervention 1: Secukinumab was supplied as a 150mg lyophiized cake in individual glass vials each. The study drug dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously. intervention 2: Secukinumab placebo was supplied as a 150mg lyophiized cake in individual glass vials each. The placebo dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.

Protocol document: